Treatment of Alcoholic Liver Disease

Comprehensive Management Approach

The American Association for the Study of Liver Diseases recommends alcohol abstinence as the primary goal for all patients with alcoholic liver disease (ALD) 1, 2
Brief interventions using the FRAMES model are effective in reducing alcohol consumption and should be implemented for all patients with ALD or hazardous drinking patterns 1, 2
Psychosocial treatments, including individual psychotherapy with cognitive behavioral therapy, group therapy, family therapy, and motivational enhancement techniques, are essential components of abstinence therapy 1, 2

Baclofen is safe and effective for alcohol abstinence in patients with advanced liver disease 2, 3
Acamprosate can be used to reduce alcohol craving and maintain abstinence in patients with ALD 1
Naltrexone should be avoided in patients with ALD due to risk of hepatotoxicity 4, 5
Disulfiram is not recommended for patients with ALD due to potential hepatotoxicity 2, 5

Active and sufficient nutritional support should be provided to all patients with ALD, with a protein intake of 1.2-1.5 g/kg/day and caloric intake of 35-40 kcal/kg/day 6
Multiple smaller meals are recommended if three regular meals cannot provide adequate nutrition 6
Vitamin and mineral supplementation, including vitamin A, thiamine, vitamin B12, folic acid, pyridoxine, vitamin D, and zinc, should be provided along with nutritional therapy 6

Corticosteroids, such as prednisolone 40 mg/day for 28 days, are recommended for severe alcoholic hepatitis with poor prognosis 6
Response to steroid treatment can be assessed using early change in bilirubin level (ECBL) at 7 days or Lille model score 6

Failure to address alcohol use disorder as the primary issue in ALD management can worsen outcomes 1, 2
Inadequate nutritional support can worsen outcomes in ALD patients who are often malnourished 6
Using hepatotoxic medications, such as naltrexone or disulfiram, in patients with advanced liver disease can increase the risk of liver damage 2, 5
Delaying corticosteroid therapy in appropriate candidates with severe alcoholic hepatitis can worsen outcomes 6
Not monitoring for response to steroid treatment using validated tools like ECBL or Lille model can lead to inadequate treatment 6
Neglecting the psychosocial aspects of alcohol dependence treatment can reduce the effectiveness of treatment 1, 2